FDA Recognizes Astellas’ Renewed Submission of Biologics License Application for Zolbetuximab and Establishes Revised Action Deadline

Today, Astellas announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Biologics License Application (BLA) for zolbetuximab, a groundbreaking investigational monoclonal antibody targeting claudin…

Read MoreFDA Recognizes Astellas’ Renewed Submission of Biologics License Application for Zolbetuximab and Establishes Revised Action Deadline

Pfizer’s LORBRENA® CROWN Trial Reveals Prolonged Progression-Free Survival for Most ALK-Positive Advanced Lung Cancer Patients Over Five Years

Today, Pfizer released extended findings from the Phase 3 CROWN trial, examining the efficacy of LORBRENA® (lorlatinib), a third-generation ALK inhibitor, versus XALKORI® (crizotinib) in previously untreated patients with ALK-positive…

Read MorePfizer’s LORBRENA® CROWN Trial Reveals Prolonged Progression-Free Survival for Most ALK-Positive Advanced Lung Cancer Patients Over Five Years